It is not often that a pharmaceutical company finds itself negotiating a 50% discount via the editorial pages of the New York Times.
That is what happened to Sanofi and Regeneron Pharmaceuticals Inc., however, with the newly approved colorectal cancer therapy Zaltrap (ziv-aflibercept). Zaltrap was singled out in an editorial on...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?